Thrombopoietin

PreclinicalSmall molecule

MM.D. Anderson Cancer Center

Thrombopoietin is one of 14 small molecule programs targeting Carboplatin. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CarboplatinCompleted

CarboplatinPreclinical

Completed

Competition

Competitive Landscape

15 competitors in Carboplatin

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Approved

35 2

Taxol

Teva

Phase 3

18 3

Avastin

Roche

Phase 3

4 4

Jevtana

Sanofi

Phase 2

1 5

Perjeta

Roche

Phase 2

1 6

Zytiga

Johnson & Johnson

Phase 2

1 7

Herceptin

OOrganon and Co

Phase 2

2 8

Rayos

RRoxane Laboratories

Phase 2

1 9

MEDI4736

AstraZeneca

Phase 2

1 10

Serplulimab

Shanghai Henlius Biotech

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Carboplatin1 trial

rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin

Completed·MM.D. Anderson Cancer Center·N/A·NCT00038012·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Thrombopoietin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thrombopoietin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thrombopoietin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MM.D. Anderson Cancer Center

Thrombopoietin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Carboplatin1 trial

References

Drug Info

Quick Facts

Related News